These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32110973)

  • 1. Mass Spectrometry-Based Identification of MHC-Associated Peptides.
    Kote S; Pirog A; Bedran G; Alfaro J; Dapic I
    Cancers (Basel); 2020 Feb; 12(3):. PubMed ID: 32110973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy.
    Zhang X; Qi Y; Zhang Q; Liu W
    Biomed Pharmacother; 2019 Dec; 120():109542. PubMed ID: 31629254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced Mass Spectrometry Detection of MHC Peptides.
    Chen R; Li J
    Methods Mol Biol; 2019; 2024():245-257. PubMed ID: 31364054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry.
    Meng W; Takeuchi Y; Ward JP; Sultan H; Arthur CD; Mardis ER; Artyomov MN; Lichti CF; Schreiber RD
    Cancer Immunol Res; 2024 Aug; 12(8):988-1006. PubMed ID: 38768391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in immunopeptidomic-based tumor neoantigen discovery.
    Meng W; Schreiber RD; Lichti CF
    Adv Immunol; 2023; 160():1-36. PubMed ID: 38042584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteogenomic Platform for Identification of Tumor Specific Antigens.
    Faktor J; Hernychová L; Vojtěšek B; Hupp T
    Klin Onkol; 2018; 31(Suppl 2):102-107. PubMed ID: 31023032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Main Strategies for the Identification of Neoantigens.
    Gopanenko AV; Kosobokova EN; Kosorukov VS
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33036391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valid-NEO: A Multi-Omics Platform for Neoantigen Detection and Quantification from Limited Clinical Samples.
    Terai YL; Huang C; Wang B; Kang X; Han J; Douglass J; Hsiue EH; Zhang M; Purohit R; deSilva T; Wang Q
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information.
    Kim S; Kim HS; Kim E; Lee MG; Shin EC; Paik S; Kim S
    Ann Oncol; 2018 Apr; 29(4):1030-1036. PubMed ID: 29360924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?
    Wirth TC; Kühnel F
    Front Immunol; 2017; 8():1848. PubMed ID: 29312332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Artificial intelligence applied in neoantigen identification facilitates personalized cancer immunotherapy.
    Cai Y; Chen R; Gao S; Li W; Liu Y; Su G; Song M; Jiang M; Jiang C; Zhang X
    Front Oncol; 2022; 12():1054231. PubMed ID: 36698417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential ion mobility mass spectrometry in immunopeptidomics identifies neoantigens carrying colorectal cancer driver mutations.
    Minegishi Y; Kiyotani K; Nemoto K; Inoue Y; Haga Y; Fujii R; Saichi N; Nagayama S; Ueda K
    Commun Biol; 2022 Aug; 5(1):831. PubMed ID: 35982173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor neoantigens: from basic research to clinical applications.
    Jiang T; Shi T; Zhang H; Hu J; Song Y; Wei J; Ren S; Zhou C
    J Hematol Oncol; 2019 Sep; 12(1):93. PubMed ID: 31492199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
    Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical Derivatization Strategy for Extending the Identification of MHC Class I Immunopeptides.
    Chen R; Fauteux F; Foote S; Stupak J; Tremblay TL; Gurnani K; Fulton KM; Weeratna RD; Twine SM; Li J
    Anal Chem; 2018 Oct; 90(19):11409-11416. PubMed ID: 30192525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.
    Müller M; Gfeller D; Coukos G; Bassani-Sternberg M
    Front Immunol; 2017; 8():1367. PubMed ID: 29104575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
    Sun Z; Chen F; Meng F; Wei J; Liu B
    Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TSNAD: an integrated software for cancer somatic mutation and tumour-specific neoantigen detection.
    Zhou Z; Lyu X; Wu J; Yang X; Wu S; Zhou J; Gu X; Su Z; Chen S
    R Soc Open Sci; 2017 Apr; 4(4):170050. PubMed ID: 28484631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteogenomics meets cancer immunology: mass spectrometric discovery and analysis of neoantigens.
    Polyakova A; Kuznetsova K; Moshkovskii S
    Expert Rev Proteomics; 2015; 12(5):533-41. PubMed ID: 26175083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.